PSA and prostate cancer screening: the challenge of the new millennium.

摘要

Prostate-specific antigen (PSA), a member of the kallikrein-type serine protease family, is highly organ-specific and abundantly produced and secreted from benign and malignant prostate epithelial cells. Serum measurements of different molecular forms of PSA and human kallikrein 2 (hK2), another member of the kallikrein family, have been used as individual biomarkers or in nomo-grams, to gain prognostic information after diagnosis or treatment of prostate cancer. The current paper will briefly discuss PSA-based screening for prostate cancer and some of the critical issues regarding the use of different forms of PSA as a present and future biomarker for detection and follow-up of men with prostate cancer.